Projects per year
Abacavir administration is associated with drug-induced hypersensitivity reactions in HIV+ individuals expressing the HLA-B*57:01 allele. However, the immunological effects of abacavir administration in an HLA-B57 mismatched transplantation setting have not been studied. We hypothesized that abacavir exposure could induce de novo HLA-B57-specific allorecognition. HIV-specific CD8 T cell clones were generated from HIV+ individuals, using single cell sorting based on HIV peptide/HLA tetramer staining. The T cell clones were assayed for alloreactivity against a panel of single HLA-expressing cell lines, in the presence or absence of abacavir. Cytokine assay, CD137 upregulation, and cytotoxicity were used as readout. Abacavir exposure can induce de novo HLA-B57 allorecognition by HIV-specific T cells. A HIV Gag RK9/HLA-A3-specific T cell did exhibit interferon-γ production, CD137 upregulation, and cytolytic effector function against allogeneic HLA-B57, but only in the presence of abacavir. Allorecognition was specific to the virus specificity, HLA restriction, and T cell receptor TRBV use of the T cell. We provide proof-of-principle evidence that administration of a drug could induce specific allorecognition of mismatched HLA molecules in the transplant setting. We suggest that HIV-seropositive recipients of an HLA-B57 mismatched graft should not receive abacavir until further studies are completed.
|Number of pages||8|
|Journal||American Journal of Transplantation|
|Publication status||E-pub ahead of print - 24 May 2019|
FingerprintDive into the research topics of 'Drug-induced alloreactivity: A new paradigm for allorecognition'. Together they form a unique fingerprint.
- 1 Finished
Stimulation of Human Immunodeficiency Virus Type 1 HIV-1 Specific Cytolytic Effector Function Using Allogeneic Cell Immunotherapy
D'Orsogna, L., John, M. & Witt, C.
National Health & Medical Research Council NHMRC
1/01/12 → 31/12/15